Northwest Biotherapeutics will announce Glioblastoma Phase 3 top line data by end of June or early July 2020, which will include IDH mutation status and strengthened MGMT status.  

$NWBO $MRK $BMY $AZN $PFE
#DCVax #DendriticCellVaccine #GBM #oncology 

https://t.co/C4m1CIywkP